Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in core spine, cardiac surgery, structural heart, cardiac pacing, and across many international markets; diabetes increases double digits as u.s. business returns to growth; raises full year guidance dublin , feb. 20, 2024 /prnewswire/ -- medtronic plc (nyse:mdt) today announced financial results for its third quarter (q3) of fiscal year 2024 (fy24), which ended january 26, 2024. key highlights revenue of $8.1 billion increased 4.7% as reported and 4.6% organic gaap diluted earnings per share (eps) of $0.99; non-gaap diluted eps of $1.30 raises fy24 organic revenue growth and eps guidance company provides portfolio management update on patient monitoring and respiratory interventions businesses received u.s. fda approval for pulseselect™ pulsed field ablation (pfa) system and percept™ rc neurostimulator with brainsense™ technology; ce mark for minimed™ 780g system with simplera sync™ cgm and micra™ av2 and micra™ vr2 leadless pacemakers financial results medtronic reported q3 worldwide revenue of $8.089 billion, an increase of 4.7% as reported and 4.6% on an organic basis.
MDT Ratings Summary
MDT Quant Ranking